Equillium (EQ) Revenue & Revenue Breakdown
Equillium Revenue Highlights
Latest Revenue (Y)
$36.08M
Latest Revenue (Q)
$12.16M
Equillium Revenue by Period
Equillium Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $36.08M | 128.97% |
| 2022-12-31 | $15.76M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Equillium generated $36.08M in revenue during NA 2023, up 128.97% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Equillium Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $12.16M | -12.21% |
| 2024-06-30 | $13.85M | 29.60% |
| 2024-03-31 | $10.69M | 16.05% |
| 2023-12-31 | $9.21M | 3.84% |
| 2023-09-30 | $8.87M | -2.78% |
| 2023-06-30 | $9.12M | 2.76% |
| 2023-03-31 | $8.88M | -43.66% |
| 2022-12-31 | $15.76M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | - |
Equillium generated $12.16M in revenue during Q3 2024, up -12.21% compared to the previous quarter, and up 133.29% compared to the same period a year ago.
Equillium Revenue Breakdown
Equillium Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 |
|---|---|
| Upfront Payment Amortization | $1.00M |
Latest
Equillium's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Upfront Payment Amortization (100.00%).
Equillium Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CHRS | Coherus BioSciences | $257.24M | $70.77M |
| SPRO | Spero Therapeutics | $96.73M | $13.47M |
| EQ | Equillium | $36.08M | $12.16M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
| IKNA | Ikena Oncology | $9.16M | - |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.14M |
| CUE | Cue Biopharma | $5.49M | $3.34M |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| LYRA | Lyra Therapeutics | $1.56M | $195.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| ANTX | AN2 Therapeutics | - | - |
| BCAB | BioAtla | - | $11.00M |
| TRVI | Trevi Therapeutics | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| JSPR | Jasper Therapeutics | - | - |
| KTTA | Pasithea Therapeutics | - | - |